Hemophilia Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hemophilia Epidemiology Forecast Report Coverage

Expert Market Research's “Hemophilia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Hemophilia. It projects the future incidence and prevalence rates of hemophilia cases across various populations. The study covers age, gender, and type as major determinants of the hemophilia population. The report highlights patterns in the prevalence of hemophilia over time and projects future trends based on multiple variables.

Hemophilia Understanding: Disease Overview

Hemophilia is a rare bleeding disorder characterized by an increased tendency for prolonged bleeding or easy bruising due to deficiency of specific clotting factors, reflecting key aspects of hemophilia pathophysiology. It is classified into multiple types and further categorized as mild, moderate, or severe based on clotting factor levels. A rare form, acquired hemophilia, occurs when autoantibodies target clotting factors. Common manifestations include easy bruising, prolonged bleeding, and painful joint bleeds (hemarthrosis), representing a typical hemophilia symptoms profile, with diagnosis confirmed through clotting factor assays.

Hemophilia Epidemiology Perspective

The hemophilia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemophilia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hemophilia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Hemophilia A is the most prevalent form of hemophilia, with estimates from the Centers for Disease Control and Prevention indicating that approximately 10 per 100,000 individuals are affected, reflecting a notable hemophilia prevalence rate.
• Hemophilia is an X-linked recessive disorder that predominantly affects males, with the vast majority of cases occurring in male populations, highlighting a distinct hemophilia gender distribution pattern.
• Global registry data suggest that females account for nearly 5% of identified hemophilia cases, representing approximately 11,700 individuals across 113 countries, indicating evolving recognition within the hemophilia patient population.
• According to the Centers for Disease Control and Prevention, diagnosis timing varies by severity, with median ages of approximately 1 month for severe cases, 8 months for moderate cases, and 36 months for mild cases, underscoring differences in hemophilia diagnosis timeline.

Read more about this report - Request a Free Sample

Country-wise Hemophilia Epidemiology Segment

The hemophilia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country-wise epidemiological patterns of hemophilia vary due to differences in healthcare infrastructure, diagnosis, and registry systems, reflecting notable hemophilia prevalence variation. In Japan, a nationwide survey reported approximately 8,751 coagulation disorder cases, including around 5,301 Hemophilia A cases, indicating a well-documented burden (Kinai et al., 2022). In contrast, the United States reports a larger patient pool, with an estimated 33,000 individuals living with hemophilia. These differences emphasize disparities in disease reporting, population size, and healthcare access across countries.

Hemophilia: Treatment Overview

Treatment for Hemophilia primarily focuses on replacing the deficient clotting factor to prevent and control bleeding episodes, reflecting advances in hemophilia treatment landscape. This is typically achieved through intravenous administration of clotting factor concentrates, either on-demand or as prophylaxis. Adjunct therapies such as desmopressin and antifibrinolytics like tranexamic acid are used in selected cases. Recent advancements include extended half-life factor products that reduce infusion frequency and non-factor therapies such as emicizumab for hemophilia A. Additionally, gene therapy offers potential for sustained endogenous clotting factor production.

Key Questions Answered

• What are the key findings of hemophilia epidemiology in the 8 major markets?
• What will be the total number of patients with hemophilia across the 8 major markets during the forecast period?
• What was the country-wise hemophilia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hemophilia patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hemophilia during the forecast period of 2026-2035?
• What are the currently available treatments for hemophilia?
• What are the disease risks, signs, symptoms, and unmet needs of hemophilia?

Scope of the Hemophilia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hemophilia based on several factors.
• Hemophilia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemophilia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hemophilia Market

Hemophilia Drug Pipeline Analysis